Search results
Results From The WOW.Com Content Network
GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin's lymphoma and Hodgkin's lymphoma. When combined with Rituximab it is called R-GemOx , R-GEMOX or GemOx-R , GEMOX-R .
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
In this case the regimen is called R-MINE or MINE-R. [citation needed] The [R]-MINE regimen consists of: Rituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones; Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R. [R]-DHAP regimen consists of: Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20; examethasone, a glucocorticoid hormone (H)igh-dose ra-C - cytarabine, an antimetabolite;
In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R. [1] R-ESHAP consists of: Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes; Etoposide, an epipodophyllotoxin topoisomerase inhibitor; Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse ...
GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1]
Gemcitabine, sold under the brand name Gemzar, among others, [1] is a chemotherapy medication used to treat cancers. [2] It is used to treat testicular cancer, [3] breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer.
This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin; this combination is called R-CHOP. In 2002, a randomized controlled trial showed a higher complete response rate for R-CHOP vs CHOP in elderly patients with Diffuse Large-B-Cell Lymphoma (76% vs 63%). [ 4 ]